{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:09:33Z","timestamp":1789232973894,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the performance of the Fetal Medicine Foundation (FMF) preterm preeclampsia (PE) screening algorithm in an indigenous South Asian population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective observational cohort study conducted in a tertiary maternal fetal unit in Delhi, India over 2\u2009years. The study population comprised of 1863 women carrying a singleton pregnancy and of South Asian ethnicity who were screened for preterm pre-eclampsia (PE) between 11 and 14\u2009weeks of gestation using Mean Arterial Pressure (MAP), transvaginal Mean Uterine Artery Pulsatility Index (UtAPI) and biochemical markers - Pregnancy Associated Plasma Protein-A (PAPP-A) and Placental Growth Factor.. Absolutemeasurements of noted biomarkers were converted to multiples of the expected gestational median (MoMS) which were then used to estimate risk for preterm PE\u2009&lt;\u200937\u2009weeks using Astraia software. Women with preterm PE risk of \u22651:100 was classified as as high risk. Detection rates (DR) at 10% false positive rate were calculated after adjusting for prophylactic aspirin use (either 75 or 150\u2009mg).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence of PE and preterm PE were 3.17% (59\/1863) and 1.34% (25\/1863) respectively. PAPP-A and PlGF MoM distribution medians were 0.86 and 0.87 MoM and significantly deviated from 1 MoM. 431 (23.1%) women had a risk of \u22651:100, 75 (17.8%) of who received aspirin. Unadjusted DR using \u22651:100 threshold was 76%.Estimated DRs for a fixed 10% FPR ranged from 52.5 to 80% depending on biomarker combination after recentering MoMs and adjusting for aspirin use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The FMF algorithm whilst performing satisfactorily could still be further improved to ensure that biophysical and biochemical markers are correctly adjusted for indigenous South Asian women.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12884-021-04283-6","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T06:02:37Z","timestamp":1638597757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Performance of Fetal Medicine Foundation algorithm for first trimester preeclampsia screening in an indigenous south Asian population"],"prefix":"10.1186","volume":"21","author":[{"given":"Smriti","family":"Prasad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daljit Singh","family":"Sahota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vanamail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshatha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"key":"4283_CR1","unstructured":"WHO | The World Health Report 2005 - make every mother and child count [Internet]. [cited 2020 May 27]. Available from: https:\/\/www.who.int\/whr\/2005\/en\/"},{"key":"4283_CR2","unstructured":"Confidential Enquiry into Maternal and Child Health (CEMACH), Perinatal Mortality 2006. England, Wales and Northern Ireland, CEMACH, London, UK; 2008."},{"key":"4283_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613\u201322.","journal-title":"N Engl J Med"},{"key":"4283_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000341264","volume":"33","author":"R Akolekar","year":"2013","unstructured":"Akolekar R, Syngelaki A, Poon L. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33:8\u201315.","journal-title":"Fetal Diagn Ther"},{"key":"4283_CR5","doi-asserted-by":"crossref","unstructured":"Wright D, Syngelaki A, Akolekar R. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015;213(62).","DOI":"10.1016\/j.ajog.2015.02.018"},{"key":"4283_CR6","doi-asserted-by":"crossref","unstructured":"O\u2019Gorman N, Wright D, Syngelaki A. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol 2016;214(103).","DOI":"10.1016\/j.ajog.2015.08.034"},{"key":"4283_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/14767058.2017.1378332","volume":"32","author":"GAR Lobo","year":"2019","unstructured":"Lobo GAR, Nowak PM, Panigassi AP. Validation of Fetal Medicine Foundation algorithm for prediction of pre-eclampsia in the first trimester in an unselected Brazilian population. J Matern Fetal Neonatal Med. 2019;32:286\u201392.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"4283_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000477934","volume":"43","author":"M Guizani","year":"2018","unstructured":"Guizani M, Valsamis J, Dutemeyer V. First-trimester combined multimarker prospective study for the detection of pregnancies at a high risk of developing preeclampsia using the Fetal Medicine Foundation-algorithm. Fetal Diagn Ther. 2018;43:266\u201373.","journal-title":"Fetal Diagn Ther"},{"key":"4283_CR9","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/ajo.12126","volume":"53","author":"FJ Park","year":"2013","unstructured":"Park FJ, Leung CH, Poon LC. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol. 2013;53:532\u20139.","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"4283_CR10","doi-asserted-by":"crossref","unstructured":"Chaemsaithong P, Pooh RK, Zheng M. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population. Am J Obstet Gynecol 2019;221(650).","DOI":"10.1016\/j.ajog.2019.09.041"},{"key":"4283_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/HYPERTENSIONAHA.117.10295","volume":"71","author":"NA Bello","year":"2018","unstructured":"Bello NA, Woolley JJ, Cleary KL. Accuracy of blood pressure measurement devices in pregnancy: a systematic review of validation studies. Hypertension. 2018;71:326\u201335.","journal-title":"Hypertension."},{"key":"4283_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000335366","volume":"31","author":"LC Poon","year":"2012","unstructured":"Poon LC, Zymeri NA, Zamprakou A, et al. Protocol for measurement of mean arterial pressure at 11-13 weeks\u2019 gestation. Fetal Diagn Ther. 2012;31:42\u20138.","journal-title":"Fetal Diagn Ther"},{"key":"4283_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000338470","volume":"32","author":"D Wright","year":"2012","unstructured":"Wright D, Akolekar R, Syngelaki A. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther. 2012;32:171\u20138.","journal-title":"Fetal Diagn Ther"},{"key":"4283_CR14","doi-asserted-by":"crossref","unstructured":"Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001;20(1):IX\u2013XIV.","DOI":"10.3109\/10641950109152635"},{"key":"4283_CR15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/uog.19039","volume":"51","author":"MY Tan","year":"2018","unstructured":"Tan MY, Wright D, Syngelaki A. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol. 2018;51:743\u201350.","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"2","key":"4283_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/uog.21905","volume":"56","author":"P Chaemsaithong","year":"2020","unstructured":"Chaemsaithong P, Sahota D, Pooh RK, Zheng M, Ma R, Chaiyasit N, et al. First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study. Ultrasound Obstet Gynecol. 2020 Aug;56(2):206\u201314.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4283_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/uog.19112","volume":"52","author":"MY Tan","year":"2018","unstructured":"Tan MY, Syngelaki A, Poon LC. Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks\u2019 gestation. Ultrasound Obstet Gynecol. 2018;52:186\u201395.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4283_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4103\/0976-9668.95955","volume":"3","author":"NK Mungreiphy","year":"2012","unstructured":"Mungreiphy NK, Dhall M, Tyagi R. Ethnicity, obesity and health pattern among Indian population. J Nat Sci Biol Med. 2012;3:52\u20139.","journal-title":"J Nat Sci Biol Med"},{"key":"4283_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/1471-0528.14970","volume":"125","author":"YKY Cheng","year":"2018","unstructured":"Cheng YKY, Leung TY, Law LW. First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study. BJOG. 2018;125:442\u20139.","journal-title":"BJOG."},{"key":"4283_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/uog.18816","volume":"50","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LCY. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol. 2017;50:492\u20135.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"4283_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3109\/10641955.2010.506232","volume":"30","author":"W Plasencia","year":"2011","unstructured":"Plasencia W, Barber MA, Alvarez EE, Segura J, Valle L, Garcia-Hernandez JA. Comparative study of transabdominal and transvaginal uterine artery Doppler pulsatility indices at 11-13+ 6 weeks. Hypertens Pregnancy. 2011;30:414\u201320.","journal-title":"Hypertens Pregnancy."},{"key":"4283_CR22","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1002\/jum.14530","volume":"37","author":"ME Demers","year":"2018","unstructured":"Demers ME, Dub\u00e9 S, Bourdages M, Gasse C, Boutin A, Girard M. Comparative study of abdominal versus transvaginal ultrasound for uterine artery Doppler velocimetry at 11 to 13 weeks. J Ultrasound Med. 2018;37:1771\u20136.","journal-title":"J Ultrasound Med"},{"key":"4283_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ajog.2016.09.076","volume":"216","author":"S Roberge","year":"2017","unstructured":"Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 2017;216:110\u201320.","journal-title":"Am J Obstet Gynecol"},{"key":"4283_CR24","doi-asserted-by":"crossref","unstructured":"Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217(685).","DOI":"10.1016\/j.ajog.2017.08.110"},{"key":"4283_CR25","unstructured":"National Family Health Survey \u22123. In: Indian Institute of Population Sciences, Mumbai Government of India [Internet]. 2005. Available from: http:\/\/rchiips.org\/NFHS\/factsheet.shtml"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-04283-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04283-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T18:05:08Z","timestamp":1638641108000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-04283-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4283"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-04283-6","relation":{},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"12 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Ethics Committee- Biomedical research, Indraprastha Apollo Hospitals, New Delhi via letter number: IAH-BMR-015\/06-20. The study was carried out in accordance with relevant guidelines and regulations and written informedconsent was obtained from pregnant women for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"805"}}